About a third of adults with spinal muscular atrophy (SMA) show signs of poor, and abnormal, lung function, according to new analyses that found breathing problems were more likely in patients with severe disease — including those with type 2 SMA and those without an ability to walk. Lower…
News
People with spinal muscular atrophy (SMA) may experience bouts of breathlessness during sleep that can look at first glance like obstructive sleep apnea (OSA), but is not associated with a blockage of the airways that defines the sleep disorder, a case study highlights. Distinguishing between true sleep apnea and…
Measuring the electrical activity of a pair of nerves that control arm movement, called the median nerves, could help assess how people with spinal muscular atrophy (SMA) respond to Evrysdi (risdiplam). That’s according to “Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic…
Disease-modifying therapies (DMTs) may slow the progression of an abnormal curvature of the spine in people with spinal muscular atrophy (SMA) type 2, a study reported. For those patients treated early, especially ones with no or minimal scoliosis, these findings were particularly significant, according to “Early treatment of…
A never-before-documented mutation in the SMN1 gene was identified as the cause of spinal muscular atrophy (SMA) type 1 for a baby in Cyprus. The case was reported in a study, “Spinal muscular atrophy type I associated with a novel SMN1 splicing variant that disrupts the expression…
Adding a small molecule to a low dose of Spinraza (nusinersen) led to enhanced therapeutic benefits in a mouse model of spinal muscular atrophy (SMA), according to a recent report. The molecule, a PRMT protein inhibitor called MS023, and Spinraza — both of which are able to boost…
For a boy with spinal muscular atrophy (SMA) who was born prematurely, treatment with Spinraza (nusinersen) until he was old enough to receive Zolgensma (onasemnogene abeparvovec) was a safe and effective therapeutic approach, according to a case report from Canada. The infant, who had been diagnosed presymptomatically…
After a year of treatment with oral Evrysdi (risdiplam), 80% of babies with pre-symptomatic spinal muscular atrophy (SMA) were able to sit without support for at least five seconds. The findings met the primary outcome measure of RAINBOWFISH, a Phase 2 clinical trial (NCT03779334) evaluating the therapy…
Breathing disruptions during sleep, which were prevalent in infants with spinal muscular atrophy (SMA), tended to improve on Zolgensma (onasemnogene abeparvovec) treatment without the need for additional interventions, according to a recent study. The only children who required treatment for sleep disordered breathing were those who had existing…
Elevated levels of neutralizing antibodies against AAV9, which can reduce the efficacy of the gene therapy Zolgensma (onasemnogene abeparvovec), were uncommon in infants and young children with spinal muscular atrophy (SMA), a study found. It also showed that anti-AAV9 antibody levels, highest in early infancy, declined over time,…
